Adamas Pharmaceuticals (ADMS) Tops Q4 EPS by 5c
Tweet
Share
E-mailGet Alerts ADMS Hot Sheet
Join SI Premium – FREE
Adamas Pharmaceuticals (NASDAQ: ADMS) reported Q4 EPS of ($0.69), $0.05 better than the analyst estimate of ($0.74).
For earnings history and earnings-related data on Adamas Pharmaceuticals (ADMS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
- Tenon Medical (TNON) Misses Q2 EPS by 395c
- Instil Bio Inc. (TIL) Misses Q2 EPS by 21c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
